Consternation as NICE rejects Janssen MS drug Ponvory

NICE has delivered its first verdict on NHS funding of Janssen's oral multiple sclerosis drug Ponvory, and it's not good news for patients with the disease waiting for new treatment options

NICE changes its mind on Novartis’ progressive MS drug Mayze...

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance.

NICE says no to Novartis’ Mayzent in secondary progressive M...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP a...